The epidemiology of Enterobacter cancerogenus is not well studied, as this bacterium is a rare cause of human infections. However, some general features can be summarized from the available literature:
Enterobacter cancerogenus is a member of the Enterobacter genus, which comprises 22 species of gram-negative bacteria that are present in the environment in large quantities and can cause opportunistic infections in plants, animals, and humans.
Enterobacter cancerogenus was formerly known as CDC Enteric Group 19 and was synonymized with Enterobacter taylorae in 1998. It is closely related to Enterobacter cloacae, a common nosocomial pathogen.
Enterobacter cancerogenus has been isolated from various sources, such as soil, water, plants, insects, animals, and humans. It has also been detected in hospital settings, like surgical wards, newborn units, and intensive care units.
Enterobacter cancerogenus can cause various types of infections, such as wound infections, bacteremia, lower respiratory tract infections, urinary tract infections, endocarditis, intraabdominal infections, septic arthritis, osteomyelitis, and ophthalmic infections. Most of these infections are associated with severe trauma or crush injuries, which may expose the patients to the environmental reservoirs of the bacterium.
Enterobacter cancerogenus is resistant to many antibiotics, such as penicillins and cephalosporins, and can Acquire genes that confer resistance to several antibiotic classes, such as carbapenems, aminoglycosides, and fluoroquinolones. Therefore, appropriate antimicrobial therapy based on susceptibility testing is required for the treatment of Enterobacter cancerogenus infections.
The prevalence and incidence of Enterobacter cancerogenus infections are unknown, as this bacterium is often misidentified or overlooked by conventional microbiological methods. Molecular methods, such as 16S rRNA gene sequencing, are needed for accurate identification and characterization of Enterobacter cancerogenus strains.
The transmission and risk factors of Enterobacter cancerogenus infections are also unclear, as there is limited epidemiological data on this bacterium. However, some possible factors that may increase the likelihood of Enterobacter cancerogenus infections are immunosuppression, underlying diseases, invasive procedures, indwelling devices, and exposure to contaminated environments.
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Enterobacter
Species: Enterobacter cancerogenus
The structure of Enterobacter cancerogenus, a rare and opportunistic pathogen, can be summarized in five points as follows:
Enterobacter cancerogenus is a Gram-negative bacterium, which means that it has a thin peptidoglycan layer and an outer membrane in its cell wall.
Enterobacter cancerogenus is a rod-shaped cell, which means that it has a cylindrical or elongated morphology.
Enterobacter cancerogenus is motile, which means that it can move by itself using its peritrichous flagella, which are hair-like appendages that surround the cell.
Enterobacter cancerogenus is encapsulated, which means that it has a polysaccharide layer outside its cell wall that protects it from the host immune system and enhances its virulence.
Enterobacter cancerogenus is a facultative anaerobe, which means that it can grow in both the presence and absence of oxygen and can use different metabolic pathways to obtain energy.
The antigenic types of Enterobacter cancerogenus have yet to be well studied, but some studies have suggested that it has different serotypes based on the O and K antigens. The O antigen is a polysaccharide component of the lipopolysaccharide (LPS) layer on the bacterium’s outer membrane. The K antigen is a capsular polysaccharide that surrounds the cell wall. These antigens can vary in structure and composition among different strains of Enterobacter cancerogenus, and they can elicit immune responses from the host.
One study identified 12 O serotypes and 8 K serotypes of Enterobacter cancerogenus by using slide agglutination and enzyme-linked immunosorbent assay (ELISA) methods. Another study found 16 O serotypes and 9 K serotypes of Enterobacter cancerogenus by utilizing molecular techniques like sequencing and polymerase chain reaction (PCR). These studies indicate that Enterobacter cancerogenus has a high degree of antigenic diversity, which may pose challenges for diagnosis and treatment.
The pathogenesis of Enterobacter cancerogenus involves multiple elements that support its propensity to spread diseases and diseases:
Antibiotic Resistance: Produces enzymes like beta-lactamases, aminoglycoside-modifying enzymes, and efflux pumps, making it resistant to various antibiotics.
Target Molecule Alteration: Modifies the structure or expression of target molecules for antibiotics, reducing their effectiveness.
Biofilm Formation: Creates biofilms that protect the bacteria from antibiotics and immune responses, promoting bacterial survival.
Immune Response Modulation: Modulates the host immune response, hindering the elimination of bacteria and causing chronic infections.
Toxin Secretion: Produces toxins that damage host cells and tissues, leading to symptoms like diarrhea, hemorrhage, and necrosis.
Secretion Systems: Possesses type I, II, and VI secretion systems, facilitating interactions with host cells and aiding in nutrient acquisition.
Lack of Type III Secretion System: Does not have a Type III secretion system, indicating a unique strategy for infection.
Curli Fimbriae Expression: Expresses curli fimbriae, which influences adhesion, aggregation, and biofilm formation, affecting the host immune response.
While these factors contribute to Enterobacter cancerogenesis pathogenicity, further research is essential to understand its molecular mechanisms and clinical implications fully.
The host defenses against Enterobacter cancerogenus are not well understood, but some general mechanisms may include:
The natural defense mechanism, which is made up of physical obstacles (such as skin and mucous membranes), cellular components (such as macrophages, neutrophils, and natural killer cells), and factors that are soluble (such as complement, cytokines, and antimicrobial peptides). These components work together to recognize and eliminate foreign invaders, such as bacteria, through phagocytosis, inflammation, and apoptosis.
The components of the adaptive immune system are antibodies and lymphocytes, including B and T cells. These components can recognize specific antigens on the surface of bacteria and mount a more specific and compelling response, such as neutralization, opsonization, and cytotoxicity.
The microbiota refers to the diverse community of microorganisms that live in and on the human body. These microorganisms can compete with pathogens for nutrients and space, produce antimicrobial substances, modulate the immune system, and impact the host genes’ expression.
However, Enterobacter cancerogenus may also have some strategies to evade or overcome the host defenses, such as:
Producing enzymes that degrade or inactivate antibiotics, such as beta-lactamases, aminoglycoside-modifying enzymes, and efflux pumps.
Altering the structure or expression of target molecules that bind to antibiotics, such as penicillin-binding proteins, ribosomes, and DNA gyrase.
Forming biofilms, which are aggregates of bacteria that adhere to surfaces and are surrounded by a matrix of extracellular polymeric substances. Biofilms can protect bacteria from antibiotics, immune cells, and environmental stresses and facilitate the exchange of genetic material.
Modulating the host immune response, such as by suppressing the production of pro-inflammatory cytokines, inducing the apoptosis of immune cells, or escaping from phagosomes.
Enterobacter cancerogenus is a Gram-negative bacterium that can cause various infections in humans, especially in those who have suffered severe trauma or crush injuries. Some of the clinical manifestations of Enterobacter cancerogenus infection are:
Lower respiratory tract infections: Infections of the lungs and airways, such as pneumonia, bronchitis, and tracheitis. Pneumonia due to Enterobacter cancerogenus can cause fever, cough, chest pain, and difficulty breathing.
Skin and soft tissue infections: skin & underlying tissue infections, such as cellulitis, abscesses, and wound infections. Redness, swelling, discomfort, and pus production can result from Enterobacter cancerogenus infections of the skin and soft tissues.
Urinary tract infections: infections affecting the kidneys, such as the bladder, kidneys, ureters, and urethra. Urinary tract infections due to Enterobacter cancerogenus can cause a burning sensation, frequency, urgency, and blood in the urine.
Endocarditis: infection of the heart’s internal lining and the heart valves. Endocarditis due to Enterobacter cancerogenus can cause fever, chills, night sweats, heart murmur, and embolic complications.
Intraabdominal infections: Infections of the organs and structures within the abdomen, such as the liver, spleen, pancreas, gallbladder, appendix, and intestines. Intraabdominal infections due to Enterobacter cancerogenus can cause abdominal pain, nausea, vomiting, diarrhea, and peritonitis.
Septic arthritis: Infection of the joints, such as the knee, hip, shoulder, and elbow. Septic arthritis due to Enterobacter cancerogenus can cause joint pain, swelling, stiffness, and reduced mobility.
Osteomyelitis: bone and bone marrow infection. Osteomyelitis due to Enterobacter cancerogenus can cause bone pain, fever, and bone destruction.
To confirm the diagnosis of Enterobacter cancerogenus infection, the following steps are recommended:
Obtain a specimen from the suspected site of infection, such as a wound swab, blood culture, sputum, urine, or tissue biopsy.
Perform a Gram stain and culture of the specimen on appropriate media, such as blood agar, MacConkey agar, or Eosin Methylene Blue agar.
Observe the colony morphology, color, and hemolysis of the cultured bacteria.
Perform biochemical tests, such as Voges-Proskauer, citrate utilization, arginine dihydrolase, malonate utilization, indole production, urea hydrolysis, lysine decarboxylase, and fermentation of various sugars, to differentiate Enterobacter cancerogenus from other Enterobacter species and related bacteria.
Perform antimicrobial susceptibility testing, such as disk diffusion, broth dilution, or automated systems, to determine the resistance profile of the isolated bacteria and guide the appropriate therapy.
Perform molecular methods, such as 16S rRNA gene sequencing, polymerase chain reaction, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, to confirm the identity and phylogeny of the isolated bacteria and detect any resistance genes.
The prevention of Enterobacter cancerogenus, a resilient and potentially harmful pathogen, involves:
Environmental Awareness: Avoid exposure to environments that may harbor Enterobacter cancerogenus, such as soil, water, plants, insects, animals, and healthcare settings.
Hygiene Practices: Adhere to good hygiene practices, including regular handwashing, proper wound care, and thorough disinfection of surfaces and equipment to prevent the transmission and colonization of Enterobacter cancerogenus.
Seek Immediate Medical Attention: If you develop symptoms of infection, including fever, pain, swelling, or redness, or if you have respiratory issues, urinary problems, gastrointestinal symptoms, joint pain, mobility issues, eye-related symptoms, or other unusual symptoms, seek immediate medical attention.
Antimicrobial Therapy Adherence: Follow prescribed antimicrobial therapy based on susceptibility testing. Avoid the misuse or overuse of antibiotics, particularly penicillins and cephalosporins, to prevent the development of antibiotic-resistant strains.
Enterobacter cancerogenus (“Enterobacter taylorae”): Infections Associated With Severe Trauma or Crush Injuries | American Journal of Clinical Pathology | Oxford Academic (oup.com)
Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance | Clinical Microbiology Reviews (asm.org)
The epidemiology of Enterobacter cancerogenus is not well studied, as this bacterium is a rare cause of human infections. However, some general features can be summarized from the available literature:
Enterobacter cancerogenus is a member of the Enterobacter genus, which comprises 22 species of gram-negative bacteria that are present in the environment in large quantities and can cause opportunistic infections in plants, animals, and humans.
Enterobacter cancerogenus was formerly known as CDC Enteric Group 19 and was synonymized with Enterobacter taylorae in 1998. It is closely related to Enterobacter cloacae, a common nosocomial pathogen.
Enterobacter cancerogenus has been isolated from various sources, such as soil, water, plants, insects, animals, and humans. It has also been detected in hospital settings, like surgical wards, newborn units, and intensive care units.
Enterobacter cancerogenus can cause various types of infections, such as wound infections, bacteremia, lower respiratory tract infections, urinary tract infections, endocarditis, intraabdominal infections, septic arthritis, osteomyelitis, and ophthalmic infections. Most of these infections are associated with severe trauma or crush injuries, which may expose the patients to the environmental reservoirs of the bacterium.
Enterobacter cancerogenus is resistant to many antibiotics, such as penicillins and cephalosporins, and can Acquire genes that confer resistance to several antibiotic classes, such as carbapenems, aminoglycosides, and fluoroquinolones. Therefore, appropriate antimicrobial therapy based on susceptibility testing is required for the treatment of Enterobacter cancerogenus infections.
The prevalence and incidence of Enterobacter cancerogenus infections are unknown, as this bacterium is often misidentified or overlooked by conventional microbiological methods. Molecular methods, such as 16S rRNA gene sequencing, are needed for accurate identification and characterization of Enterobacter cancerogenus strains.
The transmission and risk factors of Enterobacter cancerogenus infections are also unclear, as there is limited epidemiological data on this bacterium. However, some possible factors that may increase the likelihood of Enterobacter cancerogenus infections are immunosuppression, underlying diseases, invasive procedures, indwelling devices, and exposure to contaminated environments.
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Enterobacter
Species: Enterobacter cancerogenus
The structure of Enterobacter cancerogenus, a rare and opportunistic pathogen, can be summarized in five points as follows:
Enterobacter cancerogenus is a Gram-negative bacterium, which means that it has a thin peptidoglycan layer and an outer membrane in its cell wall.
Enterobacter cancerogenus is a rod-shaped cell, which means that it has a cylindrical or elongated morphology.
Enterobacter cancerogenus is motile, which means that it can move by itself using its peritrichous flagella, which are hair-like appendages that surround the cell.
Enterobacter cancerogenus is encapsulated, which means that it has a polysaccharide layer outside its cell wall that protects it from the host immune system and enhances its virulence.
Enterobacter cancerogenus is a facultative anaerobe, which means that it can grow in both the presence and absence of oxygen and can use different metabolic pathways to obtain energy.
The antigenic types of Enterobacter cancerogenus have yet to be well studied, but some studies have suggested that it has different serotypes based on the O and K antigens. The O antigen is a polysaccharide component of the lipopolysaccharide (LPS) layer on the bacterium’s outer membrane. The K antigen is a capsular polysaccharide that surrounds the cell wall. These antigens can vary in structure and composition among different strains of Enterobacter cancerogenus, and they can elicit immune responses from the host.
One study identified 12 O serotypes and 8 K serotypes of Enterobacter cancerogenus by using slide agglutination and enzyme-linked immunosorbent assay (ELISA) methods. Another study found 16 O serotypes and 9 K serotypes of Enterobacter cancerogenus by utilizing molecular techniques like sequencing and polymerase chain reaction (PCR). These studies indicate that Enterobacter cancerogenus has a high degree of antigenic diversity, which may pose challenges for diagnosis and treatment.
The pathogenesis of Enterobacter cancerogenus involves multiple elements that support its propensity to spread diseases and diseases:
Antibiotic Resistance: Produces enzymes like beta-lactamases, aminoglycoside-modifying enzymes, and efflux pumps, making it resistant to various antibiotics.
Target Molecule Alteration: Modifies the structure or expression of target molecules for antibiotics, reducing their effectiveness.
Biofilm Formation: Creates biofilms that protect the bacteria from antibiotics and immune responses, promoting bacterial survival.
Immune Response Modulation: Modulates the host immune response, hindering the elimination of bacteria and causing chronic infections.
Toxin Secretion: Produces toxins that damage host cells and tissues, leading to symptoms like diarrhea, hemorrhage, and necrosis.
Secretion Systems: Possesses type I, II, and VI secretion systems, facilitating interactions with host cells and aiding in nutrient acquisition.
Lack of Type III Secretion System: Does not have a Type III secretion system, indicating a unique strategy for infection.
Curli Fimbriae Expression: Expresses curli fimbriae, which influences adhesion, aggregation, and biofilm formation, affecting the host immune response.
While these factors contribute to Enterobacter cancerogenesis pathogenicity, further research is essential to understand its molecular mechanisms and clinical implications fully.
The host defenses against Enterobacter cancerogenus are not well understood, but some general mechanisms may include:
The natural defense mechanism, which is made up of physical obstacles (such as skin and mucous membranes), cellular components (such as macrophages, neutrophils, and natural killer cells), and factors that are soluble (such as complement, cytokines, and antimicrobial peptides). These components work together to recognize and eliminate foreign invaders, such as bacteria, through phagocytosis, inflammation, and apoptosis.
The components of the adaptive immune system are antibodies and lymphocytes, including B and T cells. These components can recognize specific antigens on the surface of bacteria and mount a more specific and compelling response, such as neutralization, opsonization, and cytotoxicity.
The microbiota refers to the diverse community of microorganisms that live in and on the human body. These microorganisms can compete with pathogens for nutrients and space, produce antimicrobial substances, modulate the immune system, and impact the host genes’ expression.
However, Enterobacter cancerogenus may also have some strategies to evade or overcome the host defenses, such as:
Producing enzymes that degrade or inactivate antibiotics, such as beta-lactamases, aminoglycoside-modifying enzymes, and efflux pumps.
Altering the structure or expression of target molecules that bind to antibiotics, such as penicillin-binding proteins, ribosomes, and DNA gyrase.
Forming biofilms, which are aggregates of bacteria that adhere to surfaces and are surrounded by a matrix of extracellular polymeric substances. Biofilms can protect bacteria from antibiotics, immune cells, and environmental stresses and facilitate the exchange of genetic material.
Modulating the host immune response, such as by suppressing the production of pro-inflammatory cytokines, inducing the apoptosis of immune cells, or escaping from phagosomes.
Enterobacter cancerogenus is a Gram-negative bacterium that can cause various infections in humans, especially in those who have suffered severe trauma or crush injuries. Some of the clinical manifestations of Enterobacter cancerogenus infection are:
Lower respiratory tract infections: Infections of the lungs and airways, such as pneumonia, bronchitis, and tracheitis. Pneumonia due to Enterobacter cancerogenus can cause fever, cough, chest pain, and difficulty breathing.
Skin and soft tissue infections: skin & underlying tissue infections, such as cellulitis, abscesses, and wound infections. Redness, swelling, discomfort, and pus production can result from Enterobacter cancerogenus infections of the skin and soft tissues.
Urinary tract infections: infections affecting the kidneys, such as the bladder, kidneys, ureters, and urethra. Urinary tract infections due to Enterobacter cancerogenus can cause a burning sensation, frequency, urgency, and blood in the urine.
Endocarditis: infection of the heart’s internal lining and the heart valves. Endocarditis due to Enterobacter cancerogenus can cause fever, chills, night sweats, heart murmur, and embolic complications.
Intraabdominal infections: Infections of the organs and structures within the abdomen, such as the liver, spleen, pancreas, gallbladder, appendix, and intestines. Intraabdominal infections due to Enterobacter cancerogenus can cause abdominal pain, nausea, vomiting, diarrhea, and peritonitis.
Septic arthritis: Infection of the joints, such as the knee, hip, shoulder, and elbow. Septic arthritis due to Enterobacter cancerogenus can cause joint pain, swelling, stiffness, and reduced mobility.
Osteomyelitis: bone and bone marrow infection. Osteomyelitis due to Enterobacter cancerogenus can cause bone pain, fever, and bone destruction.
To confirm the diagnosis of Enterobacter cancerogenus infection, the following steps are recommended:
Obtain a specimen from the suspected site of infection, such as a wound swab, blood culture, sputum, urine, or tissue biopsy.
Perform a Gram stain and culture of the specimen on appropriate media, such as blood agar, MacConkey agar, or Eosin Methylene Blue agar.
Observe the colony morphology, color, and hemolysis of the cultured bacteria.
Perform biochemical tests, such as Voges-Proskauer, citrate utilization, arginine dihydrolase, malonate utilization, indole production, urea hydrolysis, lysine decarboxylase, and fermentation of various sugars, to differentiate Enterobacter cancerogenus from other Enterobacter species and related bacteria.
Perform antimicrobial susceptibility testing, such as disk diffusion, broth dilution, or automated systems, to determine the resistance profile of the isolated bacteria and guide the appropriate therapy.
Perform molecular methods, such as 16S rRNA gene sequencing, polymerase chain reaction, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, to confirm the identity and phylogeny of the isolated bacteria and detect any resistance genes.
The prevention of Enterobacter cancerogenus, a resilient and potentially harmful pathogen, involves:
Environmental Awareness: Avoid exposure to environments that may harbor Enterobacter cancerogenus, such as soil, water, plants, insects, animals, and healthcare settings.
Hygiene Practices: Adhere to good hygiene practices, including regular handwashing, proper wound care, and thorough disinfection of surfaces and equipment to prevent the transmission and colonization of Enterobacter cancerogenus.
Seek Immediate Medical Attention: If you develop symptoms of infection, including fever, pain, swelling, or redness, or if you have respiratory issues, urinary problems, gastrointestinal symptoms, joint pain, mobility issues, eye-related symptoms, or other unusual symptoms, seek immediate medical attention.
Antimicrobial Therapy Adherence: Follow prescribed antimicrobial therapy based on susceptibility testing. Avoid the misuse or overuse of antibiotics, particularly penicillins and cephalosporins, to prevent the development of antibiotic-resistant strains.
Enterobacter cancerogenus (“Enterobacter taylorae”): Infections Associated With Severe Trauma or Crush Injuries | American Journal of Clinical Pathology | Oxford Academic (oup.com)
Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance | Clinical Microbiology Reviews (asm.org)
The epidemiology of Enterobacter cancerogenus is not well studied, as this bacterium is a rare cause of human infections. However, some general features can be summarized from the available literature:
Enterobacter cancerogenus is a member of the Enterobacter genus, which comprises 22 species of gram-negative bacteria that are present in the environment in large quantities and can cause opportunistic infections in plants, animals, and humans.
Enterobacter cancerogenus was formerly known as CDC Enteric Group 19 and was synonymized with Enterobacter taylorae in 1998. It is closely related to Enterobacter cloacae, a common nosocomial pathogen.
Enterobacter cancerogenus has been isolated from various sources, such as soil, water, plants, insects, animals, and humans. It has also been detected in hospital settings, like surgical wards, newborn units, and intensive care units.
Enterobacter cancerogenus can cause various types of infections, such as wound infections, bacteremia, lower respiratory tract infections, urinary tract infections, endocarditis, intraabdominal infections, septic arthritis, osteomyelitis, and ophthalmic infections. Most of these infections are associated with severe trauma or crush injuries, which may expose the patients to the environmental reservoirs of the bacterium.
Enterobacter cancerogenus is resistant to many antibiotics, such as penicillins and cephalosporins, and can Acquire genes that confer resistance to several antibiotic classes, such as carbapenems, aminoglycosides, and fluoroquinolones. Therefore, appropriate antimicrobial therapy based on susceptibility testing is required for the treatment of Enterobacter cancerogenus infections.
The prevalence and incidence of Enterobacter cancerogenus infections are unknown, as this bacterium is often misidentified or overlooked by conventional microbiological methods. Molecular methods, such as 16S rRNA gene sequencing, are needed for accurate identification and characterization of Enterobacter cancerogenus strains.
The transmission and risk factors of Enterobacter cancerogenus infections are also unclear, as there is limited epidemiological data on this bacterium. However, some possible factors that may increase the likelihood of Enterobacter cancerogenus infections are immunosuppression, underlying diseases, invasive procedures, indwelling devices, and exposure to contaminated environments.
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Enterobacter
Species: Enterobacter cancerogenus
The structure of Enterobacter cancerogenus, a rare and opportunistic pathogen, can be summarized in five points as follows:
Enterobacter cancerogenus is a Gram-negative bacterium, which means that it has a thin peptidoglycan layer and an outer membrane in its cell wall.
Enterobacter cancerogenus is a rod-shaped cell, which means that it has a cylindrical or elongated morphology.
Enterobacter cancerogenus is motile, which means that it can move by itself using its peritrichous flagella, which are hair-like appendages that surround the cell.
Enterobacter cancerogenus is encapsulated, which means that it has a polysaccharide layer outside its cell wall that protects it from the host immune system and enhances its virulence.
Enterobacter cancerogenus is a facultative anaerobe, which means that it can grow in both the presence and absence of oxygen and can use different metabolic pathways to obtain energy.
The antigenic types of Enterobacter cancerogenus have yet to be well studied, but some studies have suggested that it has different serotypes based on the O and K antigens. The O antigen is a polysaccharide component of the lipopolysaccharide (LPS) layer on the bacterium’s outer membrane. The K antigen is a capsular polysaccharide that surrounds the cell wall. These antigens can vary in structure and composition among different strains of Enterobacter cancerogenus, and they can elicit immune responses from the host.
One study identified 12 O serotypes and 8 K serotypes of Enterobacter cancerogenus by using slide agglutination and enzyme-linked immunosorbent assay (ELISA) methods. Another study found 16 O serotypes and 9 K serotypes of Enterobacter cancerogenus by utilizing molecular techniques like sequencing and polymerase chain reaction (PCR). These studies indicate that Enterobacter cancerogenus has a high degree of antigenic diversity, which may pose challenges for diagnosis and treatment.
The pathogenesis of Enterobacter cancerogenus involves multiple elements that support its propensity to spread diseases and diseases:
Antibiotic Resistance: Produces enzymes like beta-lactamases, aminoglycoside-modifying enzymes, and efflux pumps, making it resistant to various antibiotics.
Target Molecule Alteration: Modifies the structure or expression of target molecules for antibiotics, reducing their effectiveness.
Biofilm Formation: Creates biofilms that protect the bacteria from antibiotics and immune responses, promoting bacterial survival.
Immune Response Modulation: Modulates the host immune response, hindering the elimination of bacteria and causing chronic infections.
Toxin Secretion: Produces toxins that damage host cells and tissues, leading to symptoms like diarrhea, hemorrhage, and necrosis.
Secretion Systems: Possesses type I, II, and VI secretion systems, facilitating interactions with host cells and aiding in nutrient acquisition.
Lack of Type III Secretion System: Does not have a Type III secretion system, indicating a unique strategy for infection.
Curli Fimbriae Expression: Expresses curli fimbriae, which influences adhesion, aggregation, and biofilm formation, affecting the host immune response.
While these factors contribute to Enterobacter cancerogenesis pathogenicity, further research is essential to understand its molecular mechanisms and clinical implications fully.
The host defenses against Enterobacter cancerogenus are not well understood, but some general mechanisms may include:
The natural defense mechanism, which is made up of physical obstacles (such as skin and mucous membranes), cellular components (such as macrophages, neutrophils, and natural killer cells), and factors that are soluble (such as complement, cytokines, and antimicrobial peptides). These components work together to recognize and eliminate foreign invaders, such as bacteria, through phagocytosis, inflammation, and apoptosis.
The components of the adaptive immune system are antibodies and lymphocytes, including B and T cells. These components can recognize specific antigens on the surface of bacteria and mount a more specific and compelling response, such as neutralization, opsonization, and cytotoxicity.
The microbiota refers to the diverse community of microorganisms that live in and on the human body. These microorganisms can compete with pathogens for nutrients and space, produce antimicrobial substances, modulate the immune system, and impact the host genes’ expression.
However, Enterobacter cancerogenus may also have some strategies to evade or overcome the host defenses, such as:
Producing enzymes that degrade or inactivate antibiotics, such as beta-lactamases, aminoglycoside-modifying enzymes, and efflux pumps.
Altering the structure or expression of target molecules that bind to antibiotics, such as penicillin-binding proteins, ribosomes, and DNA gyrase.
Forming biofilms, which are aggregates of bacteria that adhere to surfaces and are surrounded by a matrix of extracellular polymeric substances. Biofilms can protect bacteria from antibiotics, immune cells, and environmental stresses and facilitate the exchange of genetic material.
Modulating the host immune response, such as by suppressing the production of pro-inflammatory cytokines, inducing the apoptosis of immune cells, or escaping from phagosomes.
Enterobacter cancerogenus is a Gram-negative bacterium that can cause various infections in humans, especially in those who have suffered severe trauma or crush injuries. Some of the clinical manifestations of Enterobacter cancerogenus infection are:
Lower respiratory tract infections: Infections of the lungs and airways, such as pneumonia, bronchitis, and tracheitis. Pneumonia due to Enterobacter cancerogenus can cause fever, cough, chest pain, and difficulty breathing.
Skin and soft tissue infections: skin & underlying tissue infections, such as cellulitis, abscesses, and wound infections. Redness, swelling, discomfort, and pus production can result from Enterobacter cancerogenus infections of the skin and soft tissues.
Urinary tract infections: infections affecting the kidneys, such as the bladder, kidneys, ureters, and urethra. Urinary tract infections due to Enterobacter cancerogenus can cause a burning sensation, frequency, urgency, and blood in the urine.
Endocarditis: infection of the heart’s internal lining and the heart valves. Endocarditis due to Enterobacter cancerogenus can cause fever, chills, night sweats, heart murmur, and embolic complications.
Intraabdominal infections: Infections of the organs and structures within the abdomen, such as the liver, spleen, pancreas, gallbladder, appendix, and intestines. Intraabdominal infections due to Enterobacter cancerogenus can cause abdominal pain, nausea, vomiting, diarrhea, and peritonitis.
Septic arthritis: Infection of the joints, such as the knee, hip, shoulder, and elbow. Septic arthritis due to Enterobacter cancerogenus can cause joint pain, swelling, stiffness, and reduced mobility.
Osteomyelitis: bone and bone marrow infection. Osteomyelitis due to Enterobacter cancerogenus can cause bone pain, fever, and bone destruction.
To confirm the diagnosis of Enterobacter cancerogenus infection, the following steps are recommended:
Obtain a specimen from the suspected site of infection, such as a wound swab, blood culture, sputum, urine, or tissue biopsy.
Perform a Gram stain and culture of the specimen on appropriate media, such as blood agar, MacConkey agar, or Eosin Methylene Blue agar.
Observe the colony morphology, color, and hemolysis of the cultured bacteria.
Perform biochemical tests, such as Voges-Proskauer, citrate utilization, arginine dihydrolase, malonate utilization, indole production, urea hydrolysis, lysine decarboxylase, and fermentation of various sugars, to differentiate Enterobacter cancerogenus from other Enterobacter species and related bacteria.
Perform antimicrobial susceptibility testing, such as disk diffusion, broth dilution, or automated systems, to determine the resistance profile of the isolated bacteria and guide the appropriate therapy.
Perform molecular methods, such as 16S rRNA gene sequencing, polymerase chain reaction, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, to confirm the identity and phylogeny of the isolated bacteria and detect any resistance genes.
The prevention of Enterobacter cancerogenus, a resilient and potentially harmful pathogen, involves:
Environmental Awareness: Avoid exposure to environments that may harbor Enterobacter cancerogenus, such as soil, water, plants, insects, animals, and healthcare settings.
Hygiene Practices: Adhere to good hygiene practices, including regular handwashing, proper wound care, and thorough disinfection of surfaces and equipment to prevent the transmission and colonization of Enterobacter cancerogenus.
Seek Immediate Medical Attention: If you develop symptoms of infection, including fever, pain, swelling, or redness, or if you have respiratory issues, urinary problems, gastrointestinal symptoms, joint pain, mobility issues, eye-related symptoms, or other unusual symptoms, seek immediate medical attention.
Antimicrobial Therapy Adherence: Follow prescribed antimicrobial therapy based on susceptibility testing. Avoid the misuse or overuse of antibiotics, particularly penicillins and cephalosporins, to prevent the development of antibiotic-resistant strains.
Enterobacter cancerogenus (“Enterobacter taylorae”): Infections Associated With Severe Trauma or Crush Injuries | American Journal of Clinical Pathology | Oxford Academic (oup.com)
Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance | Clinical Microbiology Reviews (asm.org)
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
